Search results

Records found: 23  
Your query: Sysno = ("0148615" OR "0148617" OR "0148624" OR "0148616" OR "0148505" OR "0148610" OR "0148474" OR "0148490" OR "0148625" OR "0148486" OR "0148511" OR "0148504" OR "0148537" OR "0148622" OR "0148628" OR "0148503" OR "0148484" OR "0148536" OR "0148614" OR "0148495" OR "0148471" OR "0148480" OR "0148473")

  1. 1.Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'

    Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'  / Šufliarsky J. ... [et al.] .  Onkológia. - ISSN 1336-8176 . - Roč. 13, č. 3 (2018), s. 222  
    C 3069
    article

    article

  2. 2.Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'

    Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'  / Sufliarsky J. ... [et al.] .  Onkológia. - ISSN 1336-8176 . - Roč. 13, č. 3 (2018), s. 223-224  
    C 3069
    article

    article

  3. 3.Comparison of 36 Gy, 20 Gy, or No Radiation Therapy After 6 Cycles of EBVP Chemotherapy and Complete Remission in Early-Stage Hodgkin Lymphoma Without Risk Factors: Results of the EORT-GELA H9-F Intergroup Randomized Trial

    Comparison of 36 Gy, 20 Gy, or No Radiation Therapy After 6 Cycles of EBVP Chemotherapy and Complete Remission in Early-Stage Hodgkin Lymphoma Without Risk Factors: Results of the EORT-GELA H9-F Intergroup Randomized Trial  / Vranovsky A. ... [et al.] .  Onkológia. - ISSN 1336-8176 . - Roč. 13, č. 3 (2018), s. 224  
    C 3069
    article

    article

  4. 4.Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial

    Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial  / Sufliarsky J. ... [et al.] .  Onkológia. - ISSN 1336-8176 . - Roč. 13, č. 3 (2018), s. 222-223  
    C 3069
    article

    article

  5. 5.Daratumumab v kombinovanej liečbe mnohopočetného myelómu

    Daratumumab v kombinovanej liečbe mnohopočetného myelómu  / Ľubica Harvanová, Martin Mistrík, Angelika Bátorová .  Onkológia. - ISSN 1336-8176 . - Roč. 13, č. 3 (2018), s. 216-222  : ilustr. fareb. sch. tab.  
    C 3069
    article

    article

  6. 6.ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or IImyeloid cells surface antigens [II] CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4)

    ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or IImyeloid cells surface antigens [II] CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4)  / Drgoňa L. ... [et al.] .  Onkológia. - ISSN 1336-8176 . - Roč. 13, č. 3 (2018), s. 221  
    C 3069
    article

    article

  7. 7.Extragonadálne germinatívne nádory

    Extragonadálne germinatívne nádory  / Michal Chovanec .  Onkológia. - ISSN 1336-8176 . - Roč. 13, č. 3 (2018), s. 174-177  : ilustr. schéma, obr.  
    C 3069
    article

    article

  8. 8.FLT3 mutácie u pacienta s AML: incidencia, možnosti diagnostiky a vplyv na manažment liečby

    FLT3 mutácie u pacienta s AML: incidencia, možnosti diagnostiky a vplyv na manažment liečby  / Eva Mikušková ... [et al.] .  Onkológia. - ISSN 1336-8176 . - Roč. 13, č. 3 (2018), s. 199-204  
    C 3069
    article

    article

  9. 9.Global cancer control: responding to the growing burden, rising costs and inequalities in access

    Global cancer control: responding to the growing burden, rising costs and inequalities in access  / Bystricky B. ... [et al.] .  Onkológia. - ISSN 1336-8176 . - Roč. 13, č. 3 (2018), s. 224-225  
    C 3069
    article

    article

  10. 10.Gravidita po onkologickej liečbe

    Gravidita po onkologickej liečbe  / Katarína Rejleková .  Onkológia. - ISSN 1336-8176 . - Roč. 13, č. 3 (2018), s. 190-198  : ilustr. fareb. grafy, obr., tab.  
    C 3069
    article

    article


  This site uses cookies to make them easier to browse. Learn more about how we use cookies.

Accept allSettingsReject all